-
FDA Advisory Panel Signals Support for Certain Peptides Amid Lingering Safety Questions
A US federal advisory panel has expressed support for continued access to a group of popular peptide compounds, even as regulators and scientists flag unresolved questions about their long-term safety.
-
Advisory Panel Recommends Easing Access to Widely Used Peptide Compound, Even as Safety Questions Linger
A U.S. advisory panel has voted to relax restrictions on a peptide popular in wellness and recovery circles, even though members flagged unresolved safety concerns. The recommendation now heads to federal regulators for further review.
-
Early-Stage Trial Suggests Personalized Vaccine May Help Fight Pancreatic Cancer
A Phase 1 clinical trial has reported encouraging early results for an experimental vaccine designed to help the immune system target pancreatic cancer cells. Researchers say the findings warrant further study in larger trials.
-
Peptide and Nanobody Drug Conjugates Gain Momentum as Targeted Therapy Platforms
A growing number of drug developers are building conjugate therapies around peptides and nanobodies instead of full-sized antibodies, aiming to combine precise targeting with smaller, more versatile drug scaffolds. The trend reflects broader efforts to refine how targeted payloads are delivered to specific tissues and cell types.
-
FDA Advisory Panel Recommends BPC-157 for Compounding Pharmacy List
An FDA advisory committee has voted to recommend BPC-157, a peptide widely discussed in research and wellness circles, for inclusion on the agency’s list of substances eligible for pharmacy compounding. The vote is a procedural step, not a final approval or endorsement of safety and efficacy.